Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New safety data on LYNPARZA for pancreatic cancer patients with BRCA mutation

NCT ID NCT04889404

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the safety of LYNPARZA (olaparib) when used as a maintenance treatment after platinum-based chemotherapy in 130 patients with BRCA-mutated pancreatic cancer that could not be surgically removed. Researchers tracked side effects like bone marrow problems, lung inflammation, new cancers, and harm to unborn babies. The goal was to understand real-world risks in this specific patient group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Olaparib (LYNPARZA)
What this could lead to
If successful, this study could confirm that LYNPARZA is a safe maintenance option for people with BRCA-mutated pancreatic cancer after chemotherapy.
What could go wrong
This is an observational safety study, not a test of effectiveness. It may not show clear benefits, and side effects like bone marrow depression or lung issues remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

130 people

The number who actually took part.

Started

May 2021

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients on maintenance treatment after platinum-based chemotherapy for BRCA mutated curatively unresectable pancreas cancer

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who receive LYNPARZA for the first time for the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated curatively unresectable pancreas cancer after the approval date of partial change application for the additional indication (25/Dec./2020). Exclusion Criteria: * Patients who have no treatment history with LYNPARZA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA mutated pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic neoplasms

Contacts and locations

Locations

  • Research Site

    Osaka, Lyn010001, D081FC00004, Japan

  • Research Site

    Kanagawa, Lyn010003, D081FC00004, Japan

  • Research Site

    Okayama, Lyn010004, D081FC00004, Japan

  • Research Site

    Akita, Lyn010005, D081FC00004, Japan

  • Research Site

    Niigata, Lyn010006, D081FC00004, Japan

  • Research Site

    Shizuoka, Lyn010007, D081FC00004, Japan

  • Research Site

    Niigata, Lyn010008, D081FC00004, Japan

  • Research Site

    Tokyo, Lyn010009, D081FC00004, Japan

  • Research Site

    Saitama, Lyn010010, D081FC00004, Japan

  • Research Site

    Aichi, Lyn010011, D081FC00004, Japan

  • Research Site

    Osaka, Lyn010012, D081FC00004, Japan

  • Research Site

    Tokyo, Lyn010013, D081FC00004, Japan

  • Research Site

    Nara, Lyn010014, D081FC00004, Japan

  • Research Site

    Wakayama, Lyn010015, D081FC00004, Japan

  • Research Site

    Miyagi, Lyn010016, D081FC00004, Japan

  • Research Site

    Tokyo, Lyn010017, D081FC00004, Japan

  • Research Site

    Osaka, Lyn010018, D081FC00004, Japan

  • Research Site

    Gunma, Lyn010019, D081FC00004, Japan

  • Research Site

    Hiroshima, Lyn010020, Japan

  • Research Site

    Tochigi, Lyn010021, D081FC00004, Japan

  • Research Site

    Numakunai, Lyn010022, D081FC00004, Japan

  • Research Site

    Osaka, Lyn010025, D081FC00004, Japan

  • Research Site

    Shizuoka, Lyn010026, D081FC00004, Japan

  • Research Site

    Nagasaki, Lyn010027, D081FC00004, Japan

  • Research Site

    Kumamoto, Lyn010028, D081FC00004, Japan

  • Research Site

    Saitama, Lyn010029, D081FC00004, Japan

  • Research Site

    Nagano, Lyn010031, D081FC00004, Japan

  • Research Site

    Hyōgo, Lyn010032, D081FC00004, Japan

  • Research Site

    Shimane, Lyn010033, D081FC00004, Japan

  • Research Site

    Hyōgo, Lyn010034, D081FC00004, Japan

  • Research Site

    Shizuoka, Lyn010035, D081FC00004, Japan

  • Research Site

    Hyōgo, Lyn010036, D081FC00004, Japan

  • Research Site

    Okayama, Lyn010038, D081FC00004, Japan

  • Research Site

    Fukuoka, Lyn010041, Japan

  • Research Site

    Hokkaido, Lyn010042, Japan

  • Research Site

    Ehime, Lyn010044, Japan

  • Research Site

    Osaka, Lyn010045, Japan

  • Research Site

    Shizuoka, Lyn010047, Japan

  • Research Site

    Tokyo, Lyn010050, Japan

  • Research Site

    Aichi, Japan

  • Research Site

    Chiba, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Gunma, Japan

  • Research Site

    Hiroshima, Japan

  • Research Site

    Hokkaido, Japan

  • Research Site

    Hyōgo, Japan

  • Research Site

    Ibaraki, Japan

  • Research Site

    Kagawa, Japan

  • Research Site

    Kanagawa, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Nagano, Japan

  • Research Site

    Nagasaki, Japan

  • Research Site

    Nara, Japan

  • Research Site

    Okayama, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Shizuoka, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Tottori, Japan

  • Research Site

    Toyama, Japan

  • Research Site

    Yamagata, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.